Susquehanna International Group
OCUL icon

Susquehanna International Group’s Ocular Therapeutix OCUL Stock Holding History

Susquehanna International Group’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.04M Sell
240,400
-413,300
-63% -$3.94M ﹤0.01% 6141
2025
Q4 		$7.94M Buy
653,700
+113,000
+21% +$1.37M ﹤0.01% 3349
2025
Q3 		$6.32M Buy
540,700
+441,200
+443% +$5.28M ﹤0.01% 3725
2025
Q2 		$923K Buy
99,500
+70,600
+244% +$553K ﹤0.01% 7639
2025
Q1 		$212K Sell
28,900
-92,600
-76% -$712K ﹤0.01% 10822
2024
Q4 		$1.04M Buy
121,500
+30,100
+33% +$294K ﹤0.01% 6857
2024
Q3 		$795K Buy
91,400
+18,100
+25% +$149K ﹤0.01% 7362
2024
Q2 		$501K Sell
73,300
-27,500
-27% -$170K ﹤0.01% 8255
2024
Q1 		$917K Buy
100,800
+27,700
+38% +$197K ﹤0.01% 7110
2023
Q4 		$326K Sell
73,100
-24,900
-25% -$73.6K ﹤0.01% 9651
2023
Q3 		$308K Sell
98,000
-154,200
-61% -$631K ﹤0.01% 9290
2023
Q2 		$1.3M Sell
252,200
-8,400
-3% -$50K ﹤0.01% 6083
2023
Q1 		$1.37M Buy
260,600
+177,800
+215% +$844K ﹤0.01% 6018
2022
Q4 		$233K Sell
82,800
-125,700
-60% -$416K ﹤0.01% 9747
2022
Q3 		$865K Buy
208,500
+131,900
+172% +$664K ﹤0.01% 7008
2022
Q2 		$308K Sell
76,600
-49,500
-39% -$187K ﹤0.01% 9500
2022
Q1 		$624K Buy
126,100
+8,800
+8% +$48.8K ﹤0.01% 8361
2021
Q4 		$818K Sell
117,300
-133,900
-53% -$1.04M ﹤0.01% 7825
2021
Q3 		$2.51M Sell
251,200
-16,500
-6% -$185K ﹤0.01% 5337
2021
Q2 		$3.8M Buy
267,700
+146,600
+121% +$2.23M ﹤0.01% 4537
2021
Q1 		$1.99M Buy
121,100
+49,600
+69% +$955K ﹤0.01% 5937
2020
Q4 		$1.48M Sell
71,500
-75,800
-51% -$1.13M ﹤0.01% 5765
2020
Q3 		$1.12M Sell
147,300
-70,700
-32% -$587K ﹤0.01% 5833
2020
Q2 		$1.82M Sell
218,000
-20,700
-9% -$137K ﹤0.01% 4666
2020
Q1 		$1.18M Buy
+238,700
New +$1.18M ﹤0.01% 5015
2019
Q4 		– Sell
-31,000
Closed -$94K – 10358
2019
Q3 		$94K Buy
31,000
+100
+0.3% +$447 ﹤0.01% 9589
2019
Q2 		$136K Sell
30,900
-10,300
-25% -$38.1K ﹤0.01% 9440
2019
Q1 		$164K Sell
41,200
-71,800
-64% -$289K ﹤0.01% 7985
2018
Q4 		$450K Sell
113,000
-3,100
-3% -$17.1K ﹤0.01% 6234
2018
Q3 		$799K Buy
116,100
+11,700
+11% +$73.4K ﹤0.01% 5668
2018
Q2 		$705K Sell
104,400
-27,200
-21% -$187K ﹤0.01% 6117
2018
Q1 		$857K Buy
131,600
+78,700
+149% +$443K ﹤0.01% 5587
2017
Q4 		$235K Sell
52,900
-58,500
-53% -$299K ﹤0.01% 7981
2017
Q3 		$688K Sell
111,400
-700
-0.6% -$4.51K ﹤0.01% 5963
2017
Q2 		$1.04M Sell
112,100
-140,300
-56% -$1.36M ﹤0.01% 5177
2017
Q1 		$2.34M Buy
252,400
+143,000
+131% +$1.19M ﹤0.01% 3426
2016
Q4 		$916K Sell
109,400
-69,400
-39% -$538K ﹤0.01% 5721
2016
Q3 		$1.23M Buy
178,800
+105,000
+142% +$640K ﹤0.01% 4415
2016
Q2 		$365K Buy
73,800
+9,900
+15% +$98.1K ﹤0.01% 6649
2016
Q1 		$617K Buy
63,900
+50,700
+384% +$384K ﹤0.01% 6025
2015
Q4 		$124K Sell
13,200
-15,500
-54% -$167K ﹤0.01% 8776
2015
Q3 		$404K Buy
+28,700
New +$577K ﹤0.01% 7524

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Susquehanna International Group's OCUL Position: Q1 2026 in Review

Susquehanna International Group increased its Ocular Therapeutix (OCUL) stake by 1,315% in Q1 2026, buying an estimated $1.34M and bringing the position to 150,744 shares worth $1.28M. The position accounts for ﹤0.01% of the portfolio, ranked #7272.

Susquehanna International Group first reported a position in OCUL in Q4 2015 and has held it in 35 quarters since. The position peaked at $16.6M in Q2 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Susquehanna International Group held 150,744 shares of Ocular Therapeutix worth $1.28M as of Q1 2026.
  • Susquehanna International Group bought 140,091 Ocular Therapeutix shares in Q1 2026, an estimated $1.34M.
  • Ocular Therapeutix made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7272 holding.
  • Susquehanna International Group first reported a position in Ocular Therapeutix in Q4 2015 and has held it in 35 quarters since.
  • Susquehanna International Group's Ocular Therapeutix position peaked at $16.6M in Q2 2025.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.